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agnosis, duration of disease, clinical and laboratory symptoms, procedures of di-
alysis and antianemic therapy). Health-related quality of life was assessed with
self-administrated validated version of Russian version of Euroqol-5D question-
naire. Inclusion criteria were age older than 18 years, terminal stage of chronic
renal failure and treatment with dialysis more then 4 months. RESULTS: 1395
completed questionnaires were received by September, 2010. Mean age was 42
years. 45% patients reported chronic glomerulonephritis as a main reason of
chronic renal failure, 22% - chronic pyelonephritis, 10% - diabetes, 8% - polycystic
kidney disease, other diseases – 1,5%. Average level of hemoglobin was 10716.2
g/l. 80% of patients reported that they got 12-14 procedures of dialysis during last
month. The average length of one procedure was 4-5 hours just for 17% of patients,
in other cases (80%) length of dialysis was shorter. Analysis of antianemic therapy
has shown that 85% got erytropoetins and 70% - iron supplements. More than half
of patients reported problems within each of EQ-5D dimensions of health. Thus
42.5% of patients reported problems withmobility, 20% - difficulties with self-care;
58.7% - difficulties with usual activities; 67% - reported about pain or discomfort;
47% - reported about an anxiety or depression. The average value of quality of life
evaluated with visual-analog scale (VAS) was 0.59 (SD 0.17), median – 0.6.
CONCLUSIONS:Analyses of quality of life have demonstrated high rate of problem
with usual activity and pain and discomfort and low rate of problem with self-
service.
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OBJECTIVES: To assess health status, treatment patterns and quality of life in
patients with hereditary coagulopathies in Ukraine.METHODS: Postal health sur-
vey. Questionnaires were distributed in May - August 2009. Health-related quality
of life was assessedwith self-administrated validated version of Russian version of
Euroqol-5D questionnaire. Comparison was made with data about health-related
quality of life of Russian patients (P.Vorobeyv et. al., 2008, data of 1003 patients was
used in analyses). Analysis of experimental data was performed with 2 criteria.
RESULTS: 154 completed questionnaires were received by September, 2009.
Health-related quality of lifewas assessed for patients older than 11 years (n 142).
More than half of patients reported problems within each of EQ-5D dimensions of
health. Thus 88.8% of patients reported of problems (moderate and severe) with
mobility (63.9% of Russian patients, p0.05), 57.7% of patients inform of difficulties
with self-care (35.5% of Russian patients, p0.05); 81% of patients had difficulties
with usual activity (61.9% of Russian patients, p0.05); 90.9% of patients reported of
presence of pain/discomfort (78.9% of Russian patients, p0.05); 60.5% of patients
had an anxiety or depression (54.2% of Russian patients, p0.05). The average value
of quality of life according to visual-analog scalewas 0.44 (SD 0.22). CONCLUSIONS:
The study of quality of life in patients with hereditary coagulopathies was per-
formed for the first time in Ukraine. Results of the study shown high rate of prob-
lems all aspects of health-related quality of life. Ukraine patients with hemophilia
have worse quality of life than Russian patients.
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OBJECTIVES: The fight against pain, which represents a public health challenge
and a criteria of the quality and development of a health system, above all aspires
tomeet objectives of humanity, ethics and human dignity. Physical pain andmen-
tal suffering experienced across all age groups renders those affected by illness
even more vulnerable. Pain causes incapacity, handicap and considerable deterio-
ration in the quality of life. Fighting against pain meets a legitimate expectation of
every person. METHODS: To assess the quality of life in patients suffering from
intense pain which has progressed since less than 7 days treated by a combination
of paracetamol and codeine. Amulti-centre longitudinal observational prospective
study carried out in metropolitan France using data collected by general practitio-
ners who agreed to participate. RESULTS: 574 patients treated by a paracetamol-
codeine combination (600mg/50mg and 400mg/20mg) were included; at inclusion
the quality of life assessed using SF-12was affected asmuch in terms of themental
component (41.83  7.92) as the physical component (35.88  11.68) – the norm of
the scores for each component is equal to 50 – on D7, the quality of life assessed in
a similarmanner using SF-12 was 43.31 9.89 for themental component and 40.93
7.92 for the physical component. A statistically significant improvementwas noted
for each of the 2 mental (p0.0091) and physical (p0.0001) components between
the first day of treatment and the 7th day. CONCLUSIONS: The improvement in
quality of life observed directly through SF-12 was also confirmed by patient satis-
faction: from the first day, 61% of patients declared themselves to be satisfied. On
the 7th day of treatment, 87.10% were satisfied with their treatment.
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OBJECTIVES: Congenital hemophilia is a chronic disease diagnosed early in life in
severe cases. Development of alloantibody inhibitors to exposure to replacement
factor VIII and IX concentrates is the most serious treatment complication among
patients. It is estimated that 900-1,200 patients have congenital hemophilia with
inhibitors (CHwI) in theUnited States (US). Limited research exists to document the
experience of their caregivers.METHODS: As part of a cross-sectional survey eval-
uating preservation of joint health and quality of life among CHwI patients in the
US, caregivers’ experience was assessed via the HAEMO-QoL instrument, contain-
ing an open-ended question capturing caregivers’ burden. Responses were as-
sessed for trends and consolidated into categories. Descriptive analyses were em-
ployed to evaluate caregivers’ demographic characteristics and their burden with
the disease. RESULTS: Questionnaires were received from 60 caregivers. Mean age
of patients under care was 10.6 years (SD10.3). 91.7% of patients under care had
Hemophilia A and 68.3% had high-titer inhibitors. Unemployment as a result of
caregiver responsibilities was reported by 28.1%. 31.7% reported having health
insurance with a lifetime cap. Among these, 73.7% were “somewhat” to “very con-
cerned” about reaching the cap. Among 55 HAEMO-QoL respondents 26.3% were
“considerably” to “very much so” bothered by the patient’s disease. A total of 159
open-ended responses were provided by 51 caregivers concerning their experience
about living with hemophilia and its treatment: 22.6% highlighted emotional
stress, 15.1% emphasized financial burden includingwork time, 12.0% involved lost
time excluding work, and 11.3% involved medical management issues.
CONCLUSIONS: One quarter of caregivers were “considerably” to “very much”
bothered by the patient’s condition. They reported emotional stress and financial
burden as negative experiences dealing with hemophilia and its treatment. Medi-
calmanagement is also an area of concern. A caregiver’s negative experiencemight
impact children’s HRQoL, which should be analyzed in future research.
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OBJECTIVES: The impact of lupus on patients’ everyday lives is important to un-
derstand. We therefore investigated the perceptions of lupus patients on disease
symptoms and coping strategies. METHODS: Participants (USA and Europe) com-
pleted a patient-led Internet-based questionnaire between April and May 2009.
RESULTS: 914 respondents reported having lupus (95% female, 80% 20–50 years of
age). Themost common lupus symptoms reportedwere fatigue (92%) and arthritis,
muscle pain/weakness or tendinitis (89%). Antimalarials were themost commonly
used lupus treatment (53%), followed by corticosteroids (51%). Less than half of the
respondents were satisfied/very satisfied with their current treatment (49%). Ap-
proximately one-third of respondents stated that lupus had a highly significant
effect on their careers (37%), on their physical well-being (34%) and on everyday
things (30%). Furthermore, approximately one-fifth of respondents felt that lupus
had a highly significant effect on their social life (23%) and mental health (20%),
while 11% reported it had a highly significant effect on their relationship with their
family. Most patients reported talking to family (93%) and friends (89%) about lupus
or sharing with them they had lupus (97% and 95%, respectively); 79% reported
talking to others with lupus. 77% reported it was ‘easy/very easy’ to talk to their
doctors about their symptoms. The most difficult symptoms to explain were de-
pression (45%) and CNS problems (34%). The most helpful forms of support were
understanding from family and friends (73%), ability to speak with healthcare pro-
fessionals (63%), and being connected to other lupus patients via the Internet (50%).
CONCLUSIONS: Lupus impacts greatly on patient’s everyday lives with the most
common symptom reported being fatigue. Many patients remain unsatisfied with
their treatment. Communicationwith familymembers, friends, healthcare profes-
sionals and other lupus patients are important strategies to facilitate coping with
lupus symptoms.
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OBJECTIVES: Efficacious medical or behavioral weight-loss programs are not rou-
tinely covered by insurance. Understanding how patients value weight loss inter-
ventions by assessing their willingness to pay (WTP) is critical to translating find-
ings from effectiveness trials into practice. Upon completion of a randomized
clinical trial comparing an in-person behavioral intervention to a phone/email/
web-based intervention for weight-loss, we studied participants’ WTP and charac-
teristics associated with WTP for continuing these programs. METHODS: POWER
Hopkins is an NHLBI-funded 24-month randomized clinical trial of weight loss
comparing in-person vs. call center directed coaching interventions plus web-
based education and tracking support. At the end-of-study visit, we interviewed
participants and used double bound dichotomous-choice to assess their WTP. Us-
ing linear regression, we examined baseline characteristics (age, sex, income, race,
education, and BMI) associated with WTP. RESULTS: Of the 234 adults completing
the trial to date, 206 (88%) reported on WTP. Mean age was 57 years, 61% were
women, 56.3% were White, mean BMI at baseline (2 years earlier) was 36.4 kg/m2,
33% had graduate or professional degrees, 61% had annual family income
$75,000. Participants thought their intervention was worth $70.9 (95%CI 60.3-
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81.4), and they were willing to pay $49.6/month (95%CI 44.8-54.3). Multivariate
analysis identified race as a predictor ofWTP:Whites reportedmeanWTP $18.2 (CI
8.0-28.3) less than African Americans. CONCLUSIONS: After completing a two year
trial, themajority of participants in both groups were willing to pay similar rates to
other commercially available weight loss products. The surprising racial differ-
ences in WTP seen in this high SES group need to be further examined when trial
weight outcomes are available. After a free or fully subsidized period, it might be
reasonable to implement a direct to consumer or cost sharingmechanism to better
translate effective evidence-based weight loss interventions into practice.
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OBJECTIVES: To evaluate the My Health Matters! (MHM) program, a multifaceted
workplace intervention relying on education and awareness, early detection and
disease management with a focus on risk factors for metabolic syndrome.
METHODS: The MHM program was offered to 2,000 public servants working in
more than 30worksites in British Columbia, Canada. TheMHMprogram included a
health risk assessment combined with an opportunity to attend an on-site screen-
ing and face-to-face call back visits and related on-site educational programs. Clin-
ical and economic outcomes were collected over time in this one-year prospective
study coupled with administrative and survey data. RESULTS: Forty three per cent
of employees (N857) completed the online HRA and 23 per cent (N447) attended
the initial clinical visit with the nurse. Risk factors for metabolic syndrome were
identified inmore than half of those attending the clinical visit. The number of risk
factors significantly decreased by 15 per cent over sixmonths (N141). The cost per
employee completing the HRAwas $205 while the cost per employee attending the
initial clinical visit was $394. Eighty-two per cent of employees would recommend
the program to other employers. CONCLUSIONS: This study supports that work-
place interventions are feasible, sustainable and valued by employees. As such,
this study provides a new framework for implementing and evaluating workplace
interventions focussing on metabolic disorders.
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OBJECTIVES:One third of US adults are obese and it is projected that by 2030 half of
US adults will be obese. The study aimed to identify predictors of obesity treatment
in ambulatory care settings. METHODS: National Ambulatory Care Survey
(NAMCS) 2006-07, a cross-sectional nationally representative data,was used for the
study. A retrospective cohort study design was employed; obese adults, age20
years and BMI  30 kg/m2 or having obesity diagnosis (ICD-9-CM code: 278), were
include in the cohort. Obesity treatment included either obesity counseling (diet/
nutrition, exercise, weight reduction) or pharmacotherapy (anorexiant or lipase
inhibitor). Predisposing, enabling and need characteristics as per Anderson’s be-
havioral model were included as predictor variables. Descriptive statistics and
multivariate logistic regression were conducted to identify obesity treatment pre-
dictors while preserving complex survey design of NAMCS. RESULTS: Total of 214
million visits occurred during 2006-07 by obese adults; of which, 32.66% visits re-
sulted in obesity treatment. Factors predicting obesity treatment were reason for
visit, preventive visit (OR2.23; 95% CI1.50-3.32) and chronic visit (OR1.93; 95%
CI1.46-2.55) compared to acute visit; time spent with physician, 24 minutes
(OR2.67; 95% CI1.81-3.94) and 13-24 minutes (OR1.89; 95% CI1.26-2.82) com-
pared to 0-12 minutes; high comorbidity (OR1.46; 95% CI1.13-1.89); morbidly
obese adults i.e. BMI 40 (OR1.88; 95% CI1.52-2.34) and visit to primary care
physician (OR2.38; 95% CI1.69-2.36) compared to specialist. Older adults aged
65 (OR0.98; 95% CI0.97-0.99) and smokers (OR0.52; 0.39-0.69) had less likeli-
hood of receiving obesity treatment. Gender, race, region and insurance status
were not significant predictors of obesity treatment. CONCLUSIONS: Only one
third visits resulted into obesity treatment. Reason for visit, time spent with phy-
sician, comorbidity, BMI 40, provider specialty, age and nonsmoking status were
significant predictors of obesity treatment. Future research should identify reasons
for these observed differences and efforts should be taken to deliver equitable
access.
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OBJECTIVES: Prescription monitoring programs (PMPs) have been purported to be
an effective tool to combat prescription drug abuse. However, utilization rates of
PMP data by health care practitioners is relatively low. The objectives of this study
were to determine 1) the rates of PMP request by professional affiliation per 100,000
population; 2) determine differences in rates of requests based on PMP accessibility
(online vs. other); 3) if differences exist in professional affiliation rates of requests
per 100,000 population by PMP housing agency (law enforcement agency vs. health
profession); 4) collect data on annual operating costs of PMPs per 100,000
population. METHODS: This was a cross sectional study employing a web based
survey. The survey was emailed to the 33 operational state PMP administrators
during December 2010. Descriptive statistics were used to describe PMP structure
and utilization rates. T-tests and Manova were used to determine the associations
between rates of request and PMP features. RESULTS: The preliminary response
rate was 27%. Prescribers accessed PMP datamost frequently among all authorized
users,mean requests 1,764, SD3,106. Pharmacistmean requests 171, SD220.
TheT-tests results indicate that there is a statistically significant lower request rate
for PMP datawhen housed by law enforcement administration, (t 2.5, p .04). On
average PMP annual costs were $8,146 per 100,000 population. CONCLUSIONS:
Based on preliminary results, the PMP housing entity has an impact on health care
professionals’ utilization. Online accessibility is also associatedwith an increase in
requested data reports by health care professionals. More research is needed to
determine other factors associated with PMP utilization by prescribers and phar-
macists.
PSY51
EFFECTIVENESS OF FDA’S NEW OVER-THE-COUNTER ACETAMINOPHEN LABEL
WARNING REQUIREMENTS IN IMPROVING CONSUMER RISK PERCEPTION OF
LIVER DAMAGE
Goyal RK1, Rajan SS2, Essien EJ2, Sansgiry S2
1University of North Carolina, Chapel Hill, NC, USA, 2University of Houston, Houston, TX, USA
OBJECTIVES:Thepurpose of this studywas to evaluate the effectiveness of the new
FDA mandated over-the-counter (OTC) acetaminophen organ-specific label warn-
ings, on: 1) consumer risk perception of liver damage associated with acetamino-
phen use and 2) behavioral intention to perform protective behavior.METHODS: In
this within-subject experimental study, English-speaking adults visiting OTC seg-
ments of selected pharmacy stores in Houston were conveniently recruited. Par-
ticipants were randomly exposed to both old and new label warnings and their
respective risk perception (measured on a visual analog scale, 0%, no risk, – 100%,
extreme risk) and behavioral intention (measured on a 7-point Likert scale) were
recorded using a validated, self-administered questionnaire. Descriptive statistics
and non-parametric Wilcoxon signed-rank tests were performed using SAS statis-
tical software (v9.2) at a priori significance level of 0.05. RESULTS: A total of 200
responses were collected with a response rate of 56.81%. Mean age of the sample
was 42.68 (SD 15.30) years; 48.5% of respondents weremale and 52.7%were whites.
Amajority of respondents (74.4%) were not aware of the newwarnings; however, a
majority (67.8%) had prior knowledge of the risk. The mean risk perception score
for the new label warnings was found to be significantly higher (72.2% vs. 65.9%,
p.0001) as compared to that of the old label warnings. Similarly, the average
intention score for the new labelwarningswas found to be significantly higher (5.06
vs. 4.86, p.0001) than that of the old label warnings.CONCLUSIONS: The results of
this study indicate that the new label warnings mandated by FDAmay be effective
in improving consumer risk perception of potential liver damage andmay encour-
age protective behavior. Future studies are essential to identify the impact as ac-
tual changes in consumer behavior and subsequent reduction in acetaminophen-
related morbidity and mortality.
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OBJECTIVES: To describe the potential for drug-drug interactions (DDIs) among
patients with neck and back pain diagnoses categorized into neuropathic (NEURO),
neuropathic and nociceptive(MIXED), nociceptive only (NOCI)or osteoarthritis (OA)
cohorts.METHODS:The PharMetrics USNationalmanaged care databasewas used
to identify commercially insured patients 18 to 63 years of age with at least one
claim for an opioid analgesic and a pre-existing study-related diagnosis, who were
continuously eligible for services from 9/1/2006-8/31/2008. Patients who had nurs-
ing home care claims, drug/alcohol abuse, malignancy, and spine procedures, or
pregnancy-related diagnoses were excluded. Over the 2-year study period, the fre-
quency of patients with at least 10 days of simultaneous availability of pain or
pain-related prescriptions and medications that are known inhibitors or inducers
of the cytochrome P450 (CYP) metabolic pathway was examined. RESULTS: The
analysis identified 2,375 NEURO, 37,019MIXED, 39,496 NOCI, and 6,124 OA patients.
A high prevalence of coexisting medical conditions was found in all cohorts with
40%-74% of patients having diagnoses in at least 8 different disease categories.
Based on the 10-day simultaneous drug availability criterion, the potential for DDIs
were identified in 26% of all patients during the 2-year observation period. This
percentage was highest in the MIXED cohort (31%) and lowest in the NOCI cohort
(20%). Overall, potential inhibitor interactions were found in 20% of patients and
potential inducer interactions were found in 11%. The CYP-2D6 substrates trama-
dol and oxycodone were the most frequent potential inhibitor interactions (5.6%
and 5.9% of patients, respectively). Potential inducer DDIs were most commonly
found in the CYP-1A2 pathway (8% of patients). CONCLUSIONS: Potential DDIs are
common among patients taking pain medication. Coexisting medical conditions
and their treatment, and variations in the metabolism of different pain medica-
tions contribute to the complexity of selecting analgesics thatwould be expected to
effectively treat pain.
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